Research Analysts Issue Forecasts for TNGX Q2 Earnings

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Equities research analysts at HC Wainwright issued their Q2 2027 earnings estimates for shares of Tango Therapeutics in a research note issued on Tuesday, August 18th. HC Wainwright analyst R. Burns forecasts that the company will post earnings of ($0.37) per share for the quarter. HC Wainwright has a “Buy” rating and a $68.00 price objective on the stock. The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.36) per share. HC Wainwright also issued estimates for Tango Therapeutics’ Q3 2027 earnings at ($0.39) EPS, Q4 2027 earnings at ($0.41) EPS and FY2027 earnings at ($1.54) EPS.

Tango Therapeutics (NASDAQ:TNGX) last released its earnings results on Tuesday, August 11th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.05).

Several other equities research analysts have also commented on TNGX. Stifel Nicolaus upped their price target on shares of Tango Therapeutics from $24.00 to $40.00 and gave the company a “buy” rating in a report on Monday, April 27th. JPMorgan Chase & Co. began coverage on Tango Therapeutics in a report on Wednesday, July 15th. They issued an “overweight” rating and a $46.00 price target for the company. Raymond James Financial lowered Tango Therapeutics to a “hold” rating in a research report on Thursday, June 25th. Jefferies Financial Group raised shares of Tango Therapeutics from a “hold” rating to a “buy” rating and raised their price objective for the stock from $27.00 to $60.00 in a research note on Thursday, June 25th. Finally, Canaccord Genuity Group lifted their target price on shares of Tango Therapeutics from $42.00 to $46.00 and gave the company a “buy” rating in a report on Monday, June 29th. Thirteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Tango Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.46.

Tango Therapeutics Trading Up 0.6%

Shares of NASDAQ:TNGX opened at $25.44 on Wednesday. Tango Therapeutics has a twelve month low of $6.25 and a twelve month high of $34.39. The company’s 50 day moving average is $28.69 and its 200 day moving average is $22.51. The company has a market cap of $4.29 billion, a PE ratio of -29.93 and a beta of 1.16.

Insider Transactions at Tango Therapeutics

In other Tango Therapeutics news, insider Adam Crystal sold 27,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $29.59, for a total value of $798,930.00. Following the sale, the insider directly owned 115,743 shares of the company’s stock, valued at approximately $3,424,835.37. This trade represents a 18.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 6.50% of the company’s stock.

Institutional Investors Weigh In On Tango Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Allworth Financial LP acquired a new position in Tango Therapeutics during the second quarter worth $35,000. Global Retirement Partners LLC purchased a new position in Tango Therapeutics in the 2nd quarter valued at about $122,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Tango Therapeutics by 148,800.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,467 shares of the company’s stock worth $40,000 after buying an additional 4,464 shares during the last quarter. ANTIPODES PARTNERS Ltd purchased a new stake in Tango Therapeutics during the 4th quarter worth approximately $40,000. Finally, State of Wyoming acquired a new position in shares of Tango Therapeutics during the first quarter valued at approximately $128,000. Institutional investors and hedge funds own 78.99% of the company’s stock.

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.